US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD), announced that its FXR program, including lead asset FXR314, has been acquired by Eli Lilly and Company (NYSE: LLY). The transaction grants Lilly global commercial and intellectual property rights to the program.
Transaction Details
Under the agreement, Organovo will receive an undisclosed upfront payment along with regulatory and commercial milestone payments. Lilly gains worldwide rights to develop and commercialize the FXR program, which targets IBD.
Company Background
Organovo specializes in developing therapies for IBD, while Eli Lilly is a global pharma giant with a strong presence in gastroenterology. The acquisition aligns with Lilly’s strategy to expand its pipeline in inflammatory diseases.-Fineline Info & Tech
